JOSE ACOSTA: Open Payments
NPI 1720085434 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$960 in 46 payments from 16 companies in 2025. Trend: 2023 $720 · 2024 $996 · 2025 $960
Food & beverage: $960
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $242 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $165 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $145 |
| Lilly USA, LLC | 3 | $59 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| SANOFI-AVENTIS U.S. LLC | 3 | $53 |
| Dynavax Technologies Corporation | 3 | $40 |
| PFIZER INC. | 2 | $36 |
| Abbott Laboratories | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $23 |
Products named: JARDIANCE, Kerendia, Ozempic, MOUNJARO, SHINGRIX, TZIELD, Rybelsus, Heplisav-B.
Industry payments across TX — which companies pay providers there.
